Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. - Test2 - elhamkhani - TriplyDB

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

http://www.wikidata.org/entity/Q33377654

about

Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria Paroxysmal nocturnal hemoglobinuria from bench to bedside Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome How I treat paroxysmal nocturnal hemoglobinuria Complement in Lupus Nephritis: New Perspectives Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations Inflammogenesis of Secondary Spinal Cord Injury The central role of extracellular vesicles in the mechanisms of thrombosis in paroxysmal nocturnal haemoglobinuria: a review Pesg PNH diagnosis, follow-up and treatment guidelines Implication of Complement System and its Regulators in Alzheimer’s Disease Complement inhibitor eculizumab in atypical hemolytic uremic syndrome.Immunogenicity of meningococcus C vaccination in a patient with atypical hemolytic uremic syndrome (aHUS) on eculizumab therapy.Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria.Eculizumab in paroxysmal nocturnal hemoglobinuria with Budd-Chiari syndrome progressing despite anticoagulation.Increased expression of complement regulators CD55 and CD59 on peripheral blood cells in patients with EAHEC O104:H4 infection.The importance of genetic mutation screening to determine retransplantation following failed kidney allograft from recurrent atypical haemolytic ureamic syndrome Eculizumab hepatotoxicity in pediatric aHUS.Modified Ham test for atypical hemolytic uremic syndrome Role of the skin biopsy in the diagnosis of atypical hemolytic uremic syndrome.Flow cytometry screening for paroxysmal nocturnal hemoglobinuria: A single-center experience in Saudi Arabia.Irreversible severe kidney injury and anuria in a 3-month-old girl with atypical haemolytic uraemic syndrome under administration of eculizumab.Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome.Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.Long-term remission with eculizumab in atypical haemolytic uraemic syndrome.Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry.Antineutrophilic cytoplasmic antibody-associated vasculitis with hypocomplementemia has a higher incidence of serious organ damage and a poor prognosis.A hypomorphic PIGA gene mutation causes severe defects in neuron development and susceptibility to complement-mediated toxicity in a human iPSC model Review: Complement and its regulatory proteins in kidney diseases.Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.Autocrine effects of tumor-derived complement.Paroxysmal nocturnal hemoglobinuria Clinical management of paroxysmal nocturnal haemoglobinuria in pregnancy: three case reports.The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria.Complement blockade with a C1 esterase inhibitor in paroxysmal nocturnal hemoglobinuria Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.Complement inhibition to treat myocardial infarction?Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases.Cutting edge: the membrane attack complex of complement is required for the development of murine experimental cerebral malaria.

P2860

Q24193045-BC6ADD5B-D4A4-4F92-818A-07CF5AF370F6 Q24201126-6E8DA4B3-4E2B-4A39-8EAB-5CB957E371C9 Q24599629-147DCD0A-5668-41F1-938D-CABE551BC945 Q24609286-8CFE523D-996E-4561-825D-024829357EF0 Q24622189-C5421615-BCFD-4CAF-B24D-80C320962A63 Q24648538-1C2F4555-CAA8-4C1A-AE19-4B9F9F1DB680 Q26740491-F0B4FB17-E679-45DB-A4A5-A3912D84959A Q26740877-C4FF8247-C2FD-4C9B-A605-0B02725FFA05 Q26752716-218902D2-755E-473D-8FD1-B405A8750755 Q27021748-C7C6EF3A-64CD-4F99-9EBC-C826CBB0B1AB Q27021868-4C6EFE75-EC20-42A9-9817-C781F5CE7ECF Q28972502-345E4D39-83FB-4A64-933A-6DFCE890F291 Q33385154-15988E15-0E4D-41F3-A7F0-8CB6E4B6FF29 Q33397450-14E7B1A3-1170-42C8-9978-2767C951D46E Q33403710-65E8988B-7021-4766-BA83-6446F83738E3 Q33404676-015009ED-6EDA-4509-A251-A6A4CA0E7A54 Q33410671-D6F66BBB-8831-42D0-8FF5-549EF30D68B0 Q33414227-AB2CA43D-30CB-49A7-BA1D-84C6A319BF30 Q33418797-D95420D7-3636-4332-A33D-2A3E403E8392 Q33421884-BB101C2C-7A31-47C6-8E27-9089523B0CC5 Q33422169-5F0AF891-A2E7-401E-B3B6-50E659B11002 Q33425335-10833D4F-6D0C-4035-994D-217E45E878CF Q33429572-088ABBDE-7B57-43BC-8738-C5813747857D Q33430320-EBA5FB9C-B2D4-492A-85A1-6B9BE4976431 Q33436512-000FB33A-2C80-4712-8F11-396F30F45490 Q33439129-65A80DA2-3998-4C13-9AD4-9C7672F6DE6A Q33558763-CDD23DE3-E4AD-483A-AC9D-1EA2A914BC60 Q33595396-2850A097-B66E-41D4-AEFC-29F039492864 Q33602746-0EB45A77-8849-48FE-9A5B-B81783CB01B1 Q33647738-40C29C0F-7FF9-4F33-B745-931270C6890D Q33800427-36060FCC-9C81-4DD0-9A6F-C20BD0364CCC Q33855860-E3577B64-4683-4BF2-B09C-A0D64E839CB2 Q34431429-47818D20-E3F4-4CA8-8F33-B73B4AA26661 Q34492818-3A089B18-6051-4C3F-B557-68BDD3FB7B75 Q34501102-129B4048-BBA9-4141-B366-9DFCC46E735B Q34603645-7E9D3E9E-8C24-433E-9B1D-026889295DD5 Q34626253-C4DE102D-43F1-4F82-82E4-7D0C00BE6706 Q34866828-7B00A96F-9AFD-4452-A24E-EF6D59A9453F Q34907163-C16ECE0E-BB9A-4651-ABA7-F6FD80254114 Q35032418-E8E5714E-734C-4EB5-95BE-BEBB96C81D46

P2860

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

http://www.wikidata.org/entity/Q33377654

description

2007 nî lūn-bûn

@nan

2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Multicenter phase 3 study of t ...... smal nocturnal hemoglobinuria.

@ast

Multicenter phase 3 study of t ...... smal nocturnal hemoglobinuria.

@en

Multicenter phase 3 study of t ...... smal nocturnal hemoglobinuria.

@en-gb

type

label

Multicenter phase 3 study of t ...... smal nocturnal hemoglobinuria.

@ast

Multicenter phase 3 study of t ...... smal nocturnal hemoglobinuria.

@en

Multicenter phase 3 study of t ...... smal nocturnal hemoglobinuria.

@en-gb

prefLabel

Multicenter phase 3 study of t ...... smal nocturnal hemoglobinuria.

@ast

Multicenter phase 3 study of t ...... smal nocturnal hemoglobinuria.

@en

Multicenter phase 3 study of t ...... smal nocturnal hemoglobinuria.

@en-gb

P1433

Q33377654-5E8C9953-F936-4F45-B50C-07DA8886D7B5

P1476

Q33377654-EBE108D8-BC9F-4036-B178-76EA3AE23D4C

P2093

Q33377654-31C96E87-0FCA-4C56-A2CF-8E5DBF888910

Q33377654-3276BA95-4165-4E11-9BDA-85E625CDF0F5

Q33377654-341EA09F-EE23-4C2D-A904-E2AFB75A511C

Q33377654-3771BA5D-0C9F-4778-9B72-84C505F60D1C

Q33377654-473CDB10-0A2D-4B36-AF5E-178CF151B061

Q33377654-5368AA58-2A09-4B8A-89BC-766D556C7989

Q33377654-6625B467-F245-48CE-8D97-40E0C297C818

Q33377654-698B2C57-844D-4D4B-AE09-762F53F80DC9

Q33377654-9CB6DB9B-EE4A-47EA-9C4B-870CEACBFAE8

Q33377654-BF4B070E-CDE5-428B-B29E-2FBA408975F8

P304

Q33377654-5404BF62-9FDB-42E0-806E-E35F217B02E6

P31

Q33377654-C1963F3F-3764-4040-BC31-B0AB22864F82

P356

Q33377654-A8FE4F2F-83C9-4116-A293-C73A5F2172A3

P407

Q33377654-81E25F95-FC11-46E1-91F0-D0C69438A0A8

P433

Q33377654-F7742B91-FDBE-4116-BF7D-AF85FEDF73BE

P478

Q33377654-F3E45924-93A5-4CE8-AE93-77D0D45EE648

P50

Q33377654-DD2D1816-140E-451F-82DC-46AB02600A02

P577

Q33377654-EE563439-46D0-49CB-8FCF-E452900A5B9B

P5875

Q33377654-91875CED-5E38-4990-AF4D-17CC8967ED86

P698

Q33377654-34B1122F-93FB-4863-B4DA-217B74630F50

P921

Q33377654-2EF89B82-C5ED-498A-8857-18BBD2696F47

Q33377654-7063A4A4-13E2-44D9-90CD-F97ED3011231

P356

BLOOD-2007-06-094136

P1433

P1476

Multicenter phase 3 study of t ...... smal nocturnal hemoglobinuria.

@en

P2093

Anna Gaya

http://www.w3.org/2001/XMLSchema#string

Antonio M Risitano

http://www.w3.org/2001/XMLSchema#string

Carlos de Castro

http://www.w3.org/2001/XMLSchema#string

Chieh-Lin Fu

http://www.w3.org/2001/XMLSchema#string

Elisabetta Antonioli

http://www.w3.org/2001/XMLSchema#string

Henk-André Kroon

http://www.w3.org/2001/XMLSchema#string

Hubert Schrezenmeier

http://www.w3.org/2001/XMLSchema#string

Jaroslaw P Maciejewski

http://www.w3.org/2001/XMLSchema#string

Jörg Schubert

http://www.w3.org/2001/XMLSchema#string

Luke Coyle

http://www.w3.org/2001/XMLSchema#string

P304

1840-1847

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2007-06-094136

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5792053

http://www.w3.org/2001/XMLSchema#string

P698

18055865

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial